BS-181 14361 22 nM respectively)

22 nM respectively)

Cisplatin forms highly reactive

over a period of 21 days) exhibits robust in vivo efficacy in two Pim kinases driven tumor models

iohexol is still considered a low-osmolality contrast agent

PubMed Central PMCID: PMC6711145

BS-181 14361 22 nM respectively)Normal progression through the cell cycle requires the sequential action of cyclin dependent kinases (CDK1, CDK2, CDK4 and CDK6). Deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents. As such, CDK7 is an target for the anticancer drug development. Computer modeling of CDK7 was used to design potential potent CDK7 inhibitor, which is BS 181. Product information CAS Number: